On May 20, 2026, Medtronic announced it will acquire SPR Therapeutics, a Cleveland-based maker of non-opioid chronic-pain technology, for roughly $650 million in cash. The short answer to why a company Medtronic’s size paid that much for a small, privately held device maker: SPR already owns a proven, FDA-cleared product in a fast-growing, non-opioid corner of pain management — and buying it is faster and far less risky than building the same thing from scratch. For owners of $5M–$100M businesses, the deal is a clean case study in what makes a focused company worth far more to a buyer than its size suggests.
What Medtronic actually bought for $650 million
Medtronic agreed to pay approximately $650 million in cash for all of the outstanding equity in SPR Therapeutics, a privately held medical device company founded in Cleveland in 2009. The company is not a sprawling conglomerate; it is built around a single, focused product line aimed at one large problem — chronic pain treated without opioids or permanent implants. Medtronic expects the transaction to close in the first half of its fiscal year 2027, which began on April 25, 2026, subject to the usual regulatory approvals. The company also said the deal would be only minimally dilutive to its adjusted earnings in fiscal 2027 and neutral to accretive after that, a signal that it views SPR as a durable contributor rather than a one-time bet.
The asset at the center of the deal is SPR’s SPRINT Peripheral Nerve Stimulation System, an FDA-cleared therapy that works very differently from a traditional implant. A hair-thin wire is threaded beneath the skin near a targeted nerve and connected to a small wearable device that delivers gentle electrical stimulation for up to 60 days, after which the lead is removed. There is no permanent hardware, no nerve destruction, and no addiction risk. Across its clinical record, more than 70 percent of patients have been classified as responders, a meaningfully high success rate for a chronic-pain intervention.
Medtronic framed the purchase around its five decades of neuromodulation leadership and its goal of reaching patients earlier in the care continuum. In plain terms, the company already sells advanced, permanent pain implants for severe cases; SPR gives it a less-invasive, temporary option it can offer patients sooner, before they reach the point of needing surgery. That strategic fit — a product that extends an existing franchise rather than competing with it — is exactly the kind of logic that justifies a premium price.
Why Medtronic chose to buy instead of build
Medtronic has the engineering talent and the capital to develop its own 60-day nerve-stimulation device. It chose not to, and the reasoning behind that buy-versus-build decision is the most transferable lesson in the entire deal. Building a new medical device from a blank sheet means years of research, clinical trials, and a regulatory path with no guaranteed outcome. SPR has already absorbed all of that risk and cost — the product exists, it is cleared, it is reimbursed, and it has a track record in real patients. Paying $650 million buys Medtronic several years of avoided time and a category position it could not assemble quickly on its own.
This is the same calculation that plays out in businesses far smaller than Medtronic. When a larger company acquires a smaller one, it is usually buying time, proof, and de-risked execution rather than raw assets. The smaller firm has already answered the questions that keep acquirers up at night: does the product work, will customers pay for it, and can it clear the obstacles unique to its market. An owner who understands this sees acquisition interest for what it really is — a buyer paying a premium to skip the years of uncertainty the seller has already lived through.
What makes a small company worth $650 million to a giant
SPR is not large, yet it commanded a nine-figure price because it had the handful of traits that make a focused company disproportionately valuable. It led a clearly defined category instead of dabbling across several. Its core product was proven and FDA-cleared, removing the single biggest source of doubt for a buyer. And its outcomes were documented — a responder rate north of 70 percent is the kind of evidence that turns a sales pitch into a defensible claim. None of that depended on SPR being big; it depended on SPR being focused and credible.
For owners of $5M–$100M companies, the takeaway is that acquisition value is built deliberately, not discovered by accident. The businesses that attract premium offers tend to dominate a narrow niche, run clean and well-documented operations, and can prove their results with data rather than anecdotes. That kind of operational discipline rarely happens on its own while a founder is also running sales, hiring, and everything else at once. This is precisely where focused operational leadership earns its keep; a fractional COO can help build the systems, documentation, and category focus that make a company both better to run today and more valuable to a future buyer.
It is worth noting what SPR did not do. It did not spread itself thin chasing adjacent markets, and it did not dilute its story with a dozen half-finished product lines. That restraint is part of what made it legible to an acquirer. A buyer can underwrite a clear, focused business far more confidently than a diffuse one, and that confidence shows up directly in the price.
The tailwind that made the timing work: non-opioid pain
SPR did not just have a good product; it had a good product pointed at exactly where the market and the regulatory environment are already moving. The push toward non-opioid pain management has been one of the most durable healthcare trends of the decade, driven by clinicians, payers, and policymakers who all want effective alternatives to addictive drugs. A temporary, non-addictive therapy that delivers lasting relief sits squarely in the path of that demand. Medtronic was not only buying a device; it was buying alignment with a tailwind that is likely to strengthen, not fade.
The lesson for operators is that positioning into a structural trend multiplies the value of execution. The same product launched against the current — say, a marginally better version of something the market is actively moving away from — would not command the same premium. Owners should regularly ask whether their offering is riding a tailwind or fighting a headwind, because the answer shapes both how fast the business grows and how attractive it looks to anyone who might want to buy or fund it. Timing is not luck when it is the result of deliberately building where demand is heading.
The question every owner should ask this week
The Medtronic–SPR deal is a useful mirror. The most important question it raises is not could my company sell for nine figures, but rather: if a strategic buyer looked at my business today, what would they actually be paying for — and is it documented well enough for them to believe it? For most owners, the honest answer reveals a gap between the value the business creates and the value it can prove. Closing that gap — through category focus, clean operations, and evidence of results — is work that pays off whether you ever sell or not, because the same disciplines that attract a buyer also make the business stronger and easier to run right now.
That is the work Coleman Management Advisors does with founders and operators of $5M–$100M companies: turning a business that runs on the owner’s instincts into one that runs on systems, focus, and provable results. If the SPR deal has you wondering what a serious buyer would see in your company today, let’s talk about building that value deliberately — long before you ever need to.